Stock listing

LSE:0JDI Ionis Pharmaceuticals, Inc. Share Price

UK listing (LSE) of Ionis Pharmaceuticals, Inc. · home listing NASDAQ:IONS

Follow Ionis Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · LSE:0JDI

$45.02 USD +0.89 (+2.0%)

Close on Oct 20, 2026

Day range
$43.61 – $45.33 USDOct 20, 2026
Volume
734 sharesOct 20, 2026
Ionis Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IONS · Home$45.43 USD+1.05 (+2.4%)1,716,844$44.45$45.47$44.01$44.38Close on Oct 20, 2026
LSE:0JDI$45.02 USD+0.886 (+2.0%)734$43.61$45.33$43.61$44.13Close on Oct 20, 2026
Frankfurt:ISI€39.18 EUR+0.97 (+2.5%)137€39.18€39.18€39.18€38.21Close on Oct 20, 2026
Munich:ISI€39.19 EUR+0.40 (+1.0%)—€39.19€39.19€39.19€38.79Close on Oct 20, 2026
Stuttgart:ISI€39.55 EUR+1.46 (+3.8%)—€38.15€39.56€38.11€38.09Close on Oct 19, 2026
Ticker
LSE:0JDI
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LSE
Currency
USD

What changed lately

Calls

Replays

  • Ionis Pharmaceuticals (NASDAQ:IONS) Q2 2026 Earnings Call

    Wed, Jul 29, 2026 · 8:30 AM ET

    Watch Transcript

  • Ionis Pharmaceuticals (NASDAQ:IONS) Q1 2026 Earnings Call

    Wed, Apr 29, 2026 · 8:30 AM ET

    Watch Transcript

  • Ionis Pharmaceuticals (NASDAQ:IONS) Q4 2025 Earnings Call

    Wed, Feb 25, 2026 · 8:30 AM ET

    Watch Transcript

Latest news

Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)

Oct 20, 2026

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)

Oct 16, 2026

Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

Sep 23, 2026

Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS

Sep 22, 2026

Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Sep 4, 2026

ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients

Sep 3, 2026

Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026

Aug 20, 2026

Ionis announces Dr. Frank Bennett, chief scientific officer, to retire

Jul 29, 2026

Ionis reports second quarter 2026 financial results and highlights progress on key programs

Jul 29, 2026

Ionis to hold second quarter 2026 financial results webcast

Jul 15, 2026

All Ionis Pharmaceuticals, Inc. news

Decks

Ionis Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
44 in the last 12 months · 257 in all · newest Oct 21, 2026 · oldest 2019
Calls
26 calls with a replay · 26 with a transcript · latest Jul 29, 2026
Decks
11 decks · latest Jul 29, 2026

Where Ionis Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IONS · Home listingNASDAQUnited StatesUSD
gettex:ISIgettexGermanyEUR
Lang & Schwarz:A2ACMZLang & SchwarzGermanyEUR
LS Exchange:A2ACMZLS ExchangeGermanyEUR
BX Swiss:ISIBX SwissSwitzerlandCHF
BMV:IONSBMVMexicoMXN
Milan:1IONSMilanItalyEUR
LSE:0JDI · This pageLSEUnited KingdomUSD
Frankfurt:ISIFrankfurtGermanyEUR
Dusseldorf:ISIDusseldorfGermanyEUR
Hamburg:ISIHamburgGermanyEUR
Tradegate:ISITradegateGermanyEUR
BIVA:IONSBIVAMexicoMXN
BOATS:IONSBOATSUnited StatesUSD
Munich:ISIMunichGermanyEUR
Stuttgart:ISIStuttgartGermanyEUR
Hanover:ISIHanoverGermanyEUR
Xetra:ISIXetraGermanyEUR

Log in to ask 6ix AI your own questions about Ionis Pharmaceuticals, Inc.